CAJ | 학술논문

目的：观察血小板糖蛋白IIb/IIIa受体拮抗剂替罗非班在急性心肌梗死(AMI)患者急诊介入治疗(PCI)中的有效性和安全性。方法：将行急诊PCI的患者120例，随机分为替罗非班组64例和对照组56例。比较2组梗死相关血管开通后血流情况，评估TIMI血流分级。同时观察术后与低分子肝素合用活化凝血时间(ACT)有无升高、血小板计数有无下降及出血事件发生率。结果：替罗非班组的患者梗死相关血管TIMI血流3级率为90.7%，高于对照组(P<0.05)。术后活化凝血酶原时间及血小板计数比较差异无统计学意义(P>0.05)。替罗非班不增加患者主要出血风险，但有增加微小出血的风险。结论：替罗非班在AMI急诊PCI中是安全有效的。
목적：관찰혈소판당단백IIb/IIIa수체길항제체라비반재급성심기경사(AMI)환자급진개입치료(PCI)중적유효성화안전성。방법：장행급진PCI적환자120례，수궤분위체라비반조64례화대조조56례。비교2조경사상관혈관개통후혈류정황，평고TIMI혈류분급。동시관찰술후여저분자간소합용활화응혈시간(ACT)유무승고、혈소판계수유무하강급출혈사건발생솔。결과：체라비반조적환자경사상관혈관TIMI혈류3급솔위90.7%，고우대조조(P<0.05)。술후활화응혈매원시간급혈소판계수비교차이무통계학의의(P>0.05)。체라비반불증가환자주요출혈풍험，단유증가미소출혈적풍험。결론：체라비반재AMI급진PCI중시안전유효적。
Objective:To observe drug efficacy and safety of the platelet glycoprotein IIb/IIIa receptor antagonist tirofiban in primary PCI in the treatment of patients with acute myocardial infarction(AMI). Methods:120 patients undergoing emergency PCI were randomly divided into 2 groups:64 cases in tirofiban grooup and 56 patients in control group.After the opening of the two groups were compared infarct-related artery blood flow, assess TIMI flow grade. At the same time observed the postoperative combined with low-molecular-weight heparin activated clotting time(ACT) with or without elevated platelet count whether the decreased incidence of bleeding events. Results:The infarct-related artery TIMI flow grade 3 of patients in tirofiban grooup was 90.7%, higher than that of the control group, the difference was statistically significant(P<0.05). Postoperative activation of prothrombin time and platelet count difference was not statistically significant(P<0.05). Tirofiban does not increase the risk of major bleeding in patients, but increase the risk of minor bleeding. Conclusion:Tirofiban involved in the emergency treatment of acute myocardial infarction in the process is safe and effective.